

DAFTAR PUSTAKA

- Abcam. 2010. Indirect *ELISA and Western Blotting Protocol*.
- Abbas KA, Lichtman AH, Pillai S. 2007. *Cellular and Molecular Immunology*.
Saunders Elsevier.
- Campbell NA, Reece JB, Mitchell LG. 2005. *Biologi edisi 1*. Erlangga.
- Furqan Hidayatullah, et al. 2012. *Efek Antibodi Telomerase sebagai Agen Terapi Kanker Leher Rahim; Pendekatan secara Biomolekular*. LFKKU Brawijaya.
- Gewin L. Galloway DA. 2001. *E Box-Dependent Activation Of Telomerae By Human Papillomavirus Type 16 E6 Does not Require Induction of c-myc*.
J virol. 75:7198-7201.
- Hanafiah. 2005. *Statistik Kedokteran*. Jakarta: Bumi Cipta
- M. Huh KW. 2004. *Mechanism Of Human Papilloma-Induced Oncogenesis*.
American Society For Microbiology
- Munger K. Baldwin A. Edwards KM. Hayakawa H. Nguyen CL. Owens M. Grace.
Cohen S, Graham M, Lovrecz G, Bache N, Robinson P, Reddel R (2007).
"Protein composition of catalytically active human telomerase from immortal cells". Science 315 (5820): 1850–
3doi:10.1126/science.1138596. PMID 17395830
- Robbins SL, Kumar V, Cotran RS. 2002. *Buku Ajar Patologi*. EGC.

Thorland EC. Myers L. Gostout BS. Smith DI. 2003. *Common Fragile Sites Are Preferential targets For HPV 16 Integration in Cervical Cancer Tumour. Oncogen 22: 1225-1237.*

Yves Nomine, Murielle Masson, Gilles Trave. 2006. *Structural and Functional Analysis of E6 Oncoprotein: Insights in the Molecular Pathways of Human Papillomavirus-Mediated Pathogenesis. Molecular Cell. Vol.21(5) ; 665-678. doi:10.1016/j.molcel.2006. Elsevier*

